Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	2045
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	1753
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1586
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	1063
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	423
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	312
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	245
Late-Breaking Abstracts	230
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	224
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	224
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	223
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	223
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	197
Cover Image	187
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	184
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	181
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	179
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	179
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	178
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	174
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	154
Efficacy and safety of infliximab in patients with autoimmune hepatitis	149
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	146
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	144
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	141

Access to technology to support telehealth in areas without specialty care for liver disease	138
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	134
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	133
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	129
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	125
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	120
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	115
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	114
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	113
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	112
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	112
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	112
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	111
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	110
Reply	110
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	108
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	103
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	102
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	100
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	98
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	96
Regulatory role and translational potential of CCL11 in liver fibrosis	95
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	94
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	94
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	94
	93
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	92
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	91
Genes that fit just right: Unzipping the genome of fatty liver disease	90
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	90
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	90
Therapeutic manipulation of the microbiome in liver disease	89
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	88
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	88
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	88
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	87
Reply	86
	85
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	85
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	85
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	85
Immunobiology of primary sclerosing cholangitis	82
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	82
In vivo imaging of calcium dynamics in zebrafish hepatocytes	82
Reply: The CRAPT-M score: Robust enough for clinical practice?	81
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	81
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	81
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	80
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	78
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	78

Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	78
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	77
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	77
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	76
Letter to the Editor: Overlooking the important factor: Hypoxia	76
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	74
Letter to the editor	73
The digital determinants of liver disease	72
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	70
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	70
Instructions to Authors	70
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	69
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	69
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	68
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	68
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	68
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	68
The international quest for the imaging diagnosis of liver cancer	67
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA	66
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD	66
Healthy peribiliary glands are necessary for successful liver transplantation	65
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	65
Reply: Diabetes and fibrosis—Parallel risks or overlap?	64
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	64
Fontan‐associated liver disease	64
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	63
Erratum	63
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	63
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	63
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	63
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	62
Much more needed in natural history of Alagille syndrome	62
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	62
Metabolic dysfunction-associated steatotic liver disease and the heart	61
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	61
The clot and the complicated consult	60
A strategy of vascular‐targeted therapy for liver fibrosis	60
NAFLD‐related hepatocellular carcinoma: The growing challenge	60
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	59
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	58
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response	58
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	57
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	57
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	56
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	56
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	56
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	56
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	55
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	55
Manuscript best practices: Takeaways from a community conversation	54
Reply	54
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	54
Oral Abstracts	54
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	53
Reply	53
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	53
Reply	53
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	52
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	52
Reply	52
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease	51
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	51
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	51
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	51
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	51
Hepatology Highlights	51
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	51
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	50
Reply	50
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	50
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	50
Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study	50
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	49
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	49
Integrative Hepatology: Enhancing overall health to manage liver disease	49
Glutamine synthetase loss in β-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming	49
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	49
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	48
Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	48
Pathway to global elimination of hepatitis B: HBV cure is just the first step	48

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	48
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	48
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	47
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	47
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	47
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	47
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	47
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	47
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	47
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	47
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	46
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	46
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	46
Future directions in acute liver failure	46
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	45
Masthead	45
Prognostic significance of mild ascites in patients with cirrhosis	45
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	44
Predicting liver outcomes with biomarker monitoring in MASLD	44
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	44
Intrahepatic cholangiocarcinoma PANoptosidy	44
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	44
Telehealth interventions in patients with chronic liver diseases: A systematic review	43
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	43
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	43
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	43
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	43
Letter to the Editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma	43
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	43
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	43
Presenting the new incoming editorial team for hepatology: Team members and perspectives	42
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	42
Reply	42
Table of contents	42
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	42
Masthead	42
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	42
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	41
Cover Image	41
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	41
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	41
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	41
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	40
Reply	40
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	40
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	40
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	40
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	39
The Liver Meeting: 2025 Abstracts	39
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	39
Letter to the editor: HuR in liver homeostasis	39
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	39
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	39
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	39
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	38
Letter to the Editor: Key advance in noninvasive fibrosis assessment: Evidence from China	38
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	38
Imaging for better responses to immunotherapy in hepatocellular carcinoma	38
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	38
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	38
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	38
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	38
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	38
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	37
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	37
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	37
The evolving role of liver sinusoidal endothelial cells in liver health and disease	37
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	36
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	36
A global action agenda for turning the tide on fatty liver disease	36
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	36
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	36
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	36
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	36
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	36
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	36
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	35
Category Index	35
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	35
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	35
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	35
Letter to the editor: Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury	35
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	35
Category Index	35
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	34
Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia	34
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi	34
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	34
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice	34
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC	34
MicroRNA‐206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c‐Myc mice	34
Letter to the Editor: Assessing HCC risk in HBV indeterminate phase	34
Reply: More on nonalcoholic/nonmetabolic dysfunction–associated steatohepatitis	34
Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached?	33
CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis	33